

1 Title:

2 Evaluation of a Next Generation Sequencing Assay for Hepatitis B Antiviral Drug Resistance on
3 the Oxford Nanopore System

4

5 Running Title:

6 Evaluation of a NGS Assay for HBV Drug Resistance Testing

7

8 Michael Payne ^{a b}, Gordon Ritchie ^{a b}, Tanya Lawson ^a, Matthew Young ^a, Willson Jang ^a,

9 Aleksandra Stefanovic ^{a b}, Marc G. Romney ^{a b}, Nancy Matic ^{a b}, Christopher F. Lowe ^{a b}

10

11 ^aDivision of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care,

12 Vancouver, British Columbia, Canada

13 ^bDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,

14 British Columbia, Canada

15

16 [#]Corresponding author at: Microbiology Laboratory, St. Paul's Hospital

17 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada

18 Email address: christopher.lowe@ubc.ca (C. F. Lowe)

19

20 Key Words:

21 Hepatitis B virus

22 Viral resistance testing

23 Next generation sequencing

24 Molecular methods

25

26 Word Count:1738

27

28 **Abstract**

29

30 Background: Next-generation sequencing (NGS) for Hepatitis B virus (HBV) antiviral resistance
31 (AVR) testing is a highly sensitive diagnostic method, able to detect low-level mutant
32 subpopulations. Our clinical virology laboratory previously transitioned from DNA hybridization
33 (INNO-LiPA) to NGS, initially with the GS Junior System and subsequently the MiSeq. The
34 Oxford Nanopore Technology (ONT) sequencing system was evaluated for HBV resistance
35 testing, with regards to sequencing accuracy and turn-around time.

36

37 Methods: We performed amplicon sequencing of the HBV polymerase gene from patient plasma
38 and external quality assessment (EQA) samples on the MiSeq Reagent Nano Kit v2 and GridION
39 ONT with R10.4.1 flowcells. Mutational analysis and genotyping were performed by
40 DeepChekAssay-HBV (version 2.0).

41

42 Results: A total of 49 patient samples and 15 EQA samples were tested on both the MiSeq and
43 ONT. There was high agreement for both patient and EQA samples between the MiSeq and ONT
44 systems, with regards to total drug resistance mutations detected and total patient sample
45 agreement, 68/70 (97%) and 47/49 (96%), respectively.

46

47 Conclusion: The ONT NGS platform provided accurate HBV AVR results, with improved turn-
48 around times. Sequencing error rates at AVR codons were below 1%.

49

50

51 1. Background

52 Hepatitis B virus (HBV) is an important cause of chronic hepatitis and hepatocellular carcinoma
53 (HCC) worldwide. Globally, there are an estimated 296 million people living with HBV, along
54 1.1 million deaths annually (1). Treatment of chronic HBV can decrease the risk of progression
55 to cirrhosis and HCC. Identification of the HBV genotype, along with antiviral resistance (AVR)
56 mutations, can help inform the management of chronic HBV infection (2–4). Newer antiviral
57 agents (Entecavir and Tenofovir) have a higher barrier to AVR mutations and viral
58 breakthrough; however, AVR testing is useful to monitor for emergence of mutations associated
59 with decreased virologic response, particularly for patients with previous exposure to HBV
60 antiviral therapies (3, 5).

61
62 HBV AVR line probe (LiPA) testing is limited by its inability to detect novel mutations,
63 hybridization failures, and decreased sensitivity with low viral loads (<1000 IU/mL) (6, 7). In
64 2014, testing in our clinical laboratory was transitioned to next-generation sequencing (NGS)
65 with the GS Junior System (454 Life Sciences, Branford, CT) and in 2017, the MiSeq (Illumina)
66 platform. MiSeq offered increased sequencing depth; however, a shorter read length did not
67 include all AVR mutation sites (8).

68
69 The Oxford Nanopore Technology (ONT) sequencing system (GridION ONT) with longer read
70 capability and updated R10.4.1 flowcells has reported improved error rates, allowing for more
71 accurate detection of variant subpopulations (9). In addition, this technology has less hands-on
72 library preparation and sequencing run time, allowing for improved workflow in clinical

73 laboratories. Our study aim was to optimize HBV AVR testing using NGS on the ONT platform,
74 along with validation of this test for clinical use.

75

76

77 2. Materials and Methods

78

79 We used guidance from molecular testing references and draft recommendations from the US
80 FDA to design this NGS validation study (10–12). Parameters evaluated included: Limit of
81 detection, inclusivity/accuracy, reproducibility/precision and cross-contamination. DNA was
82 extracted from samples using the MagNA Pure LC 2.0 (Roche Diagnostics, Mannheim,
83 Germany) for MiSeq and the MagNA Pure 24 (Roche) for ONT. For both ONT and MiSeq, PCR
84 primers amplified an 820 base pair (bp) region of the HBV polymerase gene on the Roche
85 LightCycler® 480. Primer sequence (5' → 3') forward (ILF) CGT GGT GGA CTT CTC TCA
86 ATT TTC and reverse (ILR) AGA AAG GCC TTG TAA GTT GGC GA. For MiSeq, the second
87 nested PCR reaction mixture consisted of the first round PCR product, and fusion indexed and
88 barcoded primers. The nested PCR final amplicon was 364 bp. ONT AVR sequencing was
89 performed using the GridION with R10.4.1 flow cells and the SQK-NBD114.24 library kit
90 (Oxford Nanopore Technologies). Guppy (v. 6.4.6) was utilized for sequence base-calling. For
91 MiSeq and ONT, mutational analysis and genotyping of FASTQ files was performed with
92 DeepChek® HBV v.2.0 (ABL SA Group). Interpretation of clinically significant AVR mutations
93 was based on the 2017 EASL Clinical Practice Guidelines (2).

94

95 The 2nd World Health Organization (WHO) International Standard for Hepatitis B Virus DNA
96 was used for evaluation of the limit of detection for the initial HBV PCR. Serial dilutions of the
97 WHO Standard were tested with 5 replicates at: 1000, 500, 250, 125, 62.5, and 30 IU/mL. Probit
98 regression was performed to determine limit of detection.

99
100 A total of 49 patient samples and 15 external quality assurance (EQA) samples (QCMD,
101 Glasgow, United Kingdom) were selected for AVR testing by NGS, to include a broad range of
102 AVR mutations, at varying viral loads and percentage mutation frequency. There were 51 patient
103 and 35 EQA samples available for genotype testing. The ATCC 45020D plasmid DNA was
104 utilized as a control in all runs to determine error rates for base calling.

105
106 To evaluate reproducibility/precision, a well characterized patient sample (genotype C; viral load
107 of 9.9×10^8 IU/mL) was utilized, with mutations at approximately 70%, 51%, 26%, and 7%, at
108 codons M204I, V173L, L180M, and T184S, respectively. The patient sample was diluted in
109 Basematrix plasma (Seracare, Milford, MA) to 10,000, 4000, 1000, 250 and 125 IU/mL. These
110 were tested in 3-5 total replicates over 2 separate NGS runs to determine the reproducibility and
111 sensitivity of NGS at detecting different percent mutations at various viral loads. In order to
112 assess cross-contamination risk, each run contained a negative control.

113

114 3. Results

115

116 There was a high agreement rate between MiSeq and ONT with regards to total mutations
117 detected and patient sample agreement, 68/70 (97%) and 47/49 (96%), respectively. All EASL

118 mutations were included in the study, with the exceptions of M250V, N236T and T184G (Table
119 1) (2).

120
121 There were two patient samples with a mutation detected only by MiSeq (Table 2). The
122 discrepant mutation results were found with low viral load samples (<2000 IU/mL). For one
123 sample, the mutant subpopulation was detected at a low frequency (4.3%, M204I) only on MiSeq
124 and would not have changed the genotypic resistance interpretation as a M204V mutation was
125 also detected at a high frequency on both MiSeq and ONT platforms. For the second sample, the
126 A181T mutation was found on MiSeq at a higher frequency (38%). QCMD samples with known
127 HBV AVR mutations were tested by MiSeq and ONT. There was 80% (12/15) agreement for
128 both platforms, with 3 samples having a L80I/V mutation identified only by the ONT platform.
129 This is a known limitation of the MiSeq assay, as the sequenced amplicon is shorter and does not
130 cover that particular mutation.

131
132 There were 35 EQA samples tested with the following genotypes: A, B, C, D, F. All were
133 identified accurately by MiSeq and ONT. A total of 51 patient samples were tested for genotype
134 by both MiSeq and ONT, and all results were concordant. These were composed of HBV
135 genotypes: A (9), B (12), C (22), D (5), E (2), and A/G (1).

136
137 ONT showed reproducible sequence variant detection for replicates with high viral loads and/or
138 high-level sequence variants (Table 3). Sequence variant detection showed increased variability
139 with low viral loads samples (<1000 IU/mL), particularly with low-level frequency
140 subpopulations (<10%). The limit of detection for the initial PCR was 119 IU/mL. From the

141 plasmid control, average base calling error rates at AVR codons were: V173 (0.74%), L180
142 (0.84%), M204 (0.36%) and M250 (0.42%). There was no evidence of sample cross-
143 contamination risk, with each runs negative control testing negative.

144
145 The ONT assay PCR and library preparation time was approximately 30% less than the MiSeq
146 assay (5 versus 7 hours for one sample with controls); however, the time required for library
147 preparation is also dependent on the number of samples included with each sequencing run.
148 Sequencing time is markedly reduced with the ONT platform: approximately 15-30 minutes for
149 ONT as compared to 23 hours for MiSeq assay. The time required for bioinformatic analysis for
150 each sample was comparable between the assays (~15 minutes).

151
152 4. Discussion

153
154 This study describes the clinical validation of a NGS HBV AVR assay using the ONT platform.
155 Results for ONT were highly concordant with MiSeq, with 100% (51/51) accuracy for genotype
156 and 96% (47/49) accuracy for AVR testing on patient samples. Two samples had an additional
157 AVR mutation detected by MiSeq which were not detected by ONT. These additional mutations
158 were detected only on MiSeq from samples with low viral loads (<2000 IU/mL). The increased
159 detection of low-level subpopulations by the MiSeq assay could be a result of the increased read
160 depth per run with the MiSeq platform (~12,500) as compared to ONT (~8000). Additionally, the
161 MiSeq assay used a more sensitive nested PCR for amplicon sequencing, which may explain
162 improved detection of AVR mutations in low viral load samples. The nested PCR step was
163 discontinued for the ONT assay, as it was more labour intensive, and had increased risks for

164 sample cross-contamination. In addition, for samples with HBV viral load <500 IU/mL, our
165 laboratory routinely reports a qualifying comment regarding decreased sensitivity for detecting
166 mutant subpopulations of <10%, which is consistent with the reproducibility results from Table
167 3. ONT was able to improve PCR/library preparation and sequencing TAT, which has been
168 previously demonstrated (13). Using the 45020D plasmid DNA control, which has a known
169 sequence, ONT sequencing error rates were found to be less than 1% (0.36-0.84%). This is
170 consistent with error rates reported for the R10.4.1 flow cells (9). Sequencing error rates are
171 minimized by further quality filtering by Q score and forward/reverse read bias performed during
172 bioinformatic analysis. This allows for confidence in reporting mutations found at a frequency of
173 3.5% or greater.

174
175 Although resistance to antiviral agents is uncommon with entecavir and tenofovir, particularly in
176 treatment-naïve patients, accessibility to HBV AVR is required for clinical follow up of patients
177 with virological breakthrough to guide treatment (2–4). While *de novo* resistance to entecavir is
178 rare, resistance can develop over time with chronic entecavir treatment: 0.9% at ≥ 5 years for
179 treatment naïve and 20.1% for nucleos/tide analogue experienced (14). Limited data exist
180 regarding tenofovir resistance, though suspected mutations have been reported which were not
181 described in the EASL guidance (2, 5). In addition to tenofovir, novel antiviral agents aiming for
182 functional cure are in the pipeline, and AVR sequencing will be needed to provide ongoing
183 surveillance for any potential novel mutations associated with drug resistance (15, 16).

184
185 There are practical barriers to the introduction of NGS in clinical laboratories, including cost,
186 technical expertise and data analysis/interpretation (17, 18). As a clinical laboratory without a

187 dedicated bioinformatician, we utilized a commercial platform to analyze FASTQ sequencing
188 data and to remove the barrier relating to bioinformatics. Laboratories can also consider other
189 commercial bioinformatic tools, which may increasingly become available as more laboratories
190 launch NGS testing programs (19). With developing infrastructure and demand for clinical
191 sequencing, laboratories may also consider the feasibility of in-house developed bioinformatic
192 pipelines to enable customization of sequence interpretation, particularly for novel
193 drugs/mutations (20).

194
195 Limitations of our study include, despite attempts to include a broad array of AVR mutations and
196 genotypes (patient and EQA samples), less frequently encountered AVR mutations and
197 genotypes could not be included. In addition, the clinical relevance of identifying low-level
198 subpopulations of AVR mutations through NGS is still unclear, and further research is required
199 to determine relevant thresholds for identification of low-level subpopulations.

200
201 In conclusion, a single real-time PCR followed by NGS with the ONT platform was found to be
202 highly accurate for the detection of HBV AVR mutations and HBV genotype testing in a clinical
203 laboratory. This was consistent across a wide variety of HBV genotypes and resistance
204 mutations. Benefits of the ONT HBV assay included increased read length, decreased sample
205 processing time, and improved TAT.

206

207

208 Conflict of Interest

209 No relevant conflict of interests to declare.

210

211 Funding

212 This research did not receive any specific grant from funding agencies in the public, commercial
213 or not-for-profit sectors.

214

215 Authorship

216 Conceptualization, MP, GR, NM, CFL; Data curation, MP, GR, TL, MY, WJ; Formal analysis,
217 MP, GR; Sequencing and analysis, GR; Funding acquisition, N/A; Investigation, MP, GR, AS,
218 MGR, NM, CFL; Methodology, GR, TL, MY; Project administration, WJ, MGR, NM, CFL;
219 Supervision, NM, CFL; Visualization, MP; Writing – original draft, MP; Writing – review &
220 editing, MP, GR, TL, MY, WJ, AS, MGR, NM, CFL.

221

222

223 References

- 224 1. World Health Organization. 2024. Guidelines for the prevention, diagnosis, care and
225 treatment for people with chronic hepatitis B infection.
- 226 2. European Association for the Study of the Liver. 2017. EASL 2017 Clinical Practice
227 Guidelines on the management of hepatitis B virus infection. *J Hepatol* 67:370–398.
- 228 3. Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH,
229 Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. 2018. Management of
230 Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the
231 Study of Liver Disease and Association of Medical Microbiology and Infectious Disease
232 Canada. *Can liver J* 1:156–217.
- 233 4. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RSJ,

- 234 Bzowej NH, Wong JB. 2018. Update on Prevention, Diagnosis, and Treatment of Chronic
235 Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Clin liver Dis* 12:33–34.
- 236 5. Mokaya J, McNaughton AL, Bester PA, Goedhals D, Barnes E, Marsden BD, Matthews
237 PC. 2020. Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature
238 review and structural analysis of drug resistance mechanisms. *Wellcome open Res.*
239 *England.*
- 240 6. Solmone M, Vincenti D, Prosperi MCF, Bruselles A, Ippolito G, Capobianchi MR. 2009.
241 Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic
242 Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect
243 Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen. *J Virol* 83:1718–
244 1726.
- 245 7. Qutub MO, Germer JJ, Rebers SPH, Mandrekar JN, Beld MGHM, Yao JDC. 2006.
246 Simplified PCR protocols for INNO-LiPA HBV Genotyping and INNO-LiPA HBV
247 PreCore assays. *J Clin Virol Off Publ Pan Am Soc Clin Virol* 37:218–221.
- 248 8. Lowe CL, Merrick L, Harrigan PR, Mazzulli T, Sherlock CH, Ritchie G. 2016. Next-
249 generation sequencing for hepatitis B genotype and resistance testing in a clinical
250 microbiology laboratory. *J Clin Microbiol* 54:127–133.
- 251 9. Kim BY, Gellert HR, Church SH, Suvorov A, Anderson SS, Barmina O, Beskid SG,
252 Comeault AA, Crown KN, Diamond SE, Dorus S, Fujichika T, Hemker JA, Hrcek J,
253 Kankare M, Katoh T, Magnacca KN, Martin RA, Matsunaga T, Medeiros MJ, Miller DE,
254 Pitnick S, Simoni S, Steenwinkel TE, Schiffer M, Syed ZA, Takahashi A, Wei KH-C,
255 Yokoyama T, Eisen MB, Kopp A, Matute D, Obbard DJ, O’Grady PM, Price DK, Toda
256 MJ, Werner T, Petrov DA. 2023. Single-fly assemblies fill major phylogenomic gaps

- 257 across the Drosophilidae Tree of Life. bioRxiv Prepr Serv Biol. United States.
- 258 10. FDA US. 2016. Infectious disease next generation sequencing based diagnostic devices:
259 microbial identification and detection of antimicrobial resistance and virulence markers:
260 draft guidance for industry and Food and Drug Administration staff. U.S. Food and Drug
261 Administration, Silver Spring, MD.
- 262 11. Burd EM. 2010. Validation of Laboratory-Developed Molecular Assays for Infectious
263 Diseases. *Clin Microbiol Rev* 23:550–576.
- 264 12. Gargis AS, Kalman L, Lubin M. 2016. Assuring the Quality of Next-Generation
265 Sequencing in Clinical Microbiology and Public Health Laboratories. *J Clin Microbiol*
266 54:2857–2865.
- 267 13. Colson P, Boschi C, Bengone-Abogourin JG, Brechard L, Motte A, Allemand I. 2021.
268 Concurrent Nanopore Next-Generation Sequencing of Hepatitis B and Delta Virus
269 Genomes Directly From Patient Plasma. *Ann Lab Med. Korea (South)*.
- 270 14. Lumley SF, Delphin M, Mokaya JF, Tan CCS, Martyn E, Anderson M, Li KC, Waddilove
271 E, Sukali G, Downs LO, Said K, Okanda D, Campbell C, Harriss E, Shimakawa Y,
272 Matthews PC. 2024. A systematic review and meta-analysis of the risk of hepatitis B virus
273 (HBV) resistance in people treated with entecavir or tenofovir. *J Clin Virol Off Publ Pan*
274 *Am Soc Clin Virol* 174:105711.
- 275 15. Wong GLH, Gane E, Lok ASF. 2022. How to achieve functional cure of HBV: Stopping
276 NUCs, adding interferon or new drug development? *J Hepatol* 76:1249–1262.
- 277 16. Yuen M-F, Lim S-G, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu
278 CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz
279 N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata

- 280 A, Cremer J, Elston R, Lukić T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F,
281 Paff M, Theodore D. 2022. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B
282 Infection. *N Engl J Med* 387:1957–1968.
- 283 17. Boers SA, Jansen R, Hays JP. 2019. Understanding and overcoming the pitfalls and biases
284 of next-generation sequencing (NGS) methods for use in the routine clinical
285 microbiological diagnostic laboratory. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc*
286 *Clin Microbiol* 38:1059–1070.
- 287 18. Greninger AL. 2018. The challenge of diagnostic metagenomics. *Expert Rev Mol Diagn*
288 18:605–615.
- 289 19. Ringlander J, Andersson ME, Prakash K, Larsson SB, Lindh M. 2022. Deep sequencing
290 of hepatitis B virus using Ion Torrent fusion primer method. *J Virol Methods* 299:114315.
- 291 20. Wang H. 2024. Practical updates in clinical antiviral resistance testing. *J Clin Microbiol*
292 62:e0072823.
- 293
- 294

295 Table 1 Hepatitis B Antiviral Resistance Mutations Identified by Next Generation Sequencing

EASL Mutation	Number Identified ONT	Number Identified MiSeq
M204V	16	16
M204I	12	13
L180M	25	25
A181T/V	1	2
N236T	0	0
I169T	1	1
V173L	7	7
M250V	0	0
T184G	0	0
S202I/G	6	6
Total Mutations	68	70
Samples Negative for Mutations	39	38

296 EASL: European Association for the Study of the Liver

297 NGS: Next-generation sequencing

298 ONT: Oxford Nanopore

299

300

301

302

303

304 Table 2 Discordant Result Analysis

Sample	Genotype	Viral Load (IU/mL)	ONT	MiSeq
1	D	1,360	L180M M204V	L180M M204V M204I(4.3%)
2	C	1,710		A181T(38%)

305 ONT: Oxford Nanopore

306

307

308 Table 3 Reproducibility in minority variant analysis with
 309 decreasing viral loads

Variant	Viral Load (IU/mL)	ONT	
		Mean (%)	Coefficient of variation
M204I	10000	70.3	7.8
	4000	67.7	10.8
	1000	72.0	17.6
	250	89.3	17.1
	125	41.6	115.8
V173L	10000	50.5	7.5
	4000	48.2	10.1
	1000	61.4	22.3
	250	45.2	84.5
	125	24.0	195.3
L180M	10000	25.7	21.6
	4000	31.7	24.8
	1000	25.0	48.3
	250	7.9	190.7
	125	54.5	86.5
T184S	10000	6.5	16.4
	4000	10.3	92.7
	1000	1.1	120.9
	250	2.5	95.2
	125	0.3	15.4

310 ONT: Oxford Nanopore

311

312

313